PDF
ePub
Citation
Print
Abstract
Noncardiac chest pain (NCCP) is defined as recurring, angina-like, retrosternal chest pain of noncardiac origin. Although patients with NCCP have excellent long-term prognosis, most suffer persistently from their symptoms. Several pathophysiological mechanisms have been suggested, including gastroesophageal reflux disease (GERD), esophageal motility disorder, esophageal hyper-sensitivity, and psychological comorbidity. Among them, GERD is the most common cause of NCCP. Therefore, GERD should first be considered as the underlying cause of symptoms in patients with NCCP. Empirical proton pump inhibitor (PPI) treatment with a preferably double dose for more than 2 months could be cost-effective. PPI test can also be used for diagnosis of GERD-related NCCP, but it should be considered for patients with NCCP occurring at least weekly and its duration should be at least 2 weeks. However, upper endoscopy and esophageal pH monitoring are necessary when the diagnosis of GERD is uncertain. Esophageal impedance-pH monitoring could further improve the diagnostic yield. Patients with GERD-related NCCP should preferably be treated with a double dose PPI until symptoms remit (may require more than 2 months of therapy for optimal symptom control), followed by dose tapering to determine the lowest PPI dose that can control symptoms. However, treatment of patients with non-GERD− related NCCP is challenging. An empirical treatment of antidepressants could be considered. If there are specific esophageal motility disorders, smooth muscle relaxants or endoscopic treatment may be considered in selected cases. If none of these traditional treatments is effective, a psychology consultation for cognitive behavioral therapy should be considered.)
References
1. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011; 17:110–123.
2. Krarup AL, Liao D, Gregersen H, et al. Nonspecific motility disorders, irritable esophagus, and chest pain. Ann N Y Acad Sci. 2013; 1300:96–109.
3. Jerlock M, Welin C, Rosengren A, Gaston-Johansson F. Pain characteristics in patients with unexplained chest pain and patients with ischemic heart disease. Eur J Cardiovasc Nurs. 2007; 6:130–136.
4. Fass R, Navarro-Rodriguez T. Noncardiac chest pain. J Clin Gastroenterol. 2008; 42:636–646.
5. Dumville JC, MacPherson H, Griffith K, Miles JN, Lewin RJ. Noncardiac chest pain: a retrospective cohort study of patients who attended a Rapid Access Chest Pain Clinic. Fam Pract. 2007; 24:152–157.
6. Ford AC, Suares NC, Talley NJ. Meta-analysis: the epidemiology of noncardiac chest pain in the community. Aliment Pharmacol Ther. 2011; 34:172–180.
7. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol. 2005; 100:747–753.
8. Eslick GD. Noncardiac chest pain: epidemiology, natural history, health care seeking, and quality of life. Gastroenterol Clin North Am. 2004; 33:1–23.
9. Karlson BW, Wiklund I, Bengtson A, Herlitz J. Prognosis, severity of symptoms, and aspects of well-being among patients in whom myocardial infarction was ruled out. Clin Cardiol. 1994; 17:427–431.
10. Tew R, Guthrie EA, Creed FH, Cotter L, Kisely S, Tomenson B. A long-term follow-up study of patients with ischaemic heart disease versus patients with nonspecific chest pain. J Psychosom Res. 1995; 39:977–985.
11. Wielgosz AT, Fletcher RH, McCants CB, McKinnis RA, Haney TL, Williams RB. Unimproved chest pain in patients with minimal or no coronary disease: a behavioral phenomenon. Am Heart J. 1984; 108:67–72.
12. Potts SG, Bass CM. Psychological morbidity in patients with chest pain and normal or near-normal coronary arteries: a long-term follow-up study. Psychol Med. 1995; 25:339–347.
13. Eslick GD, Talley NJ. Natural history and predictors of outcome for non-cardiac chest pain: a prospective 4-year cohort study. Neurogastroenterol Motil. 2008; 20:989–997.
14. Eslick GD, Talley NJ. Noncardiac chest pain: squeezing the life out of the Australian healthcare system? Med J Aust. 2000; 173:233–234.
15. Fass R, Achem SR. Noncardiac chest pain: diagnostic evaluation. Dis Esophagus. 2012; 25:89–101.
16. Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997; 42:2138–2145.
17. Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut. 2011; 60:1473–1478.
18. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009; 125:666–673.
19. Kapoor N, Bassi A, Sturgess R, Bodger K. Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. Gut. 2005; 54:40–45.
20. Dickman R, Mattek N, Holub J, Peters D, Fass R. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol. 2007; 102:1173–1179.
21. Nasr I, Attaluri A, Coss-Adame E, Rao SS. Diagnostic utility of the oesophageal balloon distension test in the evaluation of oesophageal chest pain. Aliment Pharmacol Ther. 2012; 35:1474–1481.
22. DeMeester TR, O'Sullivan GC, Bermudez G, Midell AI, Cimochowski GE, O'Drobinak J. Esophageal function in patients with angi-na-type chest pain and normal coronary angiograms. Ann Surg. 1982; 196:488–498.
23. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with non-cardiac chest pain. Gastroenterology. 1998; 115:42–49.
24. Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, place-bo-controlled, crossover trial. Aliment Pharmacol Ther. 2005; 22:547–555.
25. Kim JH, Sinn DH, Son HJ, Kim JJ, Rhee JC, Rhee PL. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol. 2009; 24:1504–1509.
26. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012; 61:1340–1354.
27. Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: ‘on’ or ‘off’ proton pump inhibitor? Am J Gastroenterol. 2008; 103:2446–2453.
28. Frazzoni M, Conigliaro R, Melotti G. Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis. Aliment Pharmacol Ther. 2011; 33:601–606.
29. Kim BJ, Choi SC, Kim JJ, Rhee JC, Rhee PL. Pathological bolus exposure plays a significant role in eliciting non-cardiac chest pain. J Gastroenterol Hepatol. 2010; 25:1855–1860.
30. Kim JH, Rhee PL, Park EH, Son HJ, Kim JJ, Rhee JC. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. J Gastroenterol Hepatol. 2007; 22:320–325.
31. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol. 2002; 35:307–314.
32. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2003; 17:369–377.
33. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain–a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2004; 19:1123–1130.
34. Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med. 2005; 165:1222–1228.
35. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R. The cost-ef-fectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med. 1999; 107:219–227.
36. Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther. 2007; 25:103–109.
37. Pandolfino JE, Kahrilas PJ. American Gastroenterological Association. American Gastroenterological Association medical position statement: clinical use of esophageal manometry. Gastroenterology. 2005; 128:207–208.
38. Katz PO, Dalton CB, Richter JE, Wu WC, Castell DO. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med. 1987; 106:593–597.
39. Dekel R, Pearson T, Wendel C, De Garmo P, Fennerty MB, Fass R. Assessment of oesophageal motor function in patients with dysphagia or chest pain: the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther. 2003; 18:1083–1089.
40. Kessing BF, Bredenoord AJ, Smout AJ. Erroneous diagnosis of gastroesophageal reflux disease in achalasia. Clin Gastroenterol Hepatol. 2011; 9:1020–1024.
41. Ponce J, Ortiz V, Maroto N, Ponce M, Bustamante M, Garrigues V. High prevalence of heartburn and low acid sensitivity in patients with idiopathic achalasia. Dig Dis Sci. 2011; 56:773–776.
42. Ko WJ, Lee BM, Park WY, et al. Jackhammer esophagus treated by a peroral endoscopic myotomy. Korean J Gastroenterol. 2014; 64:370–374.
43. Lufrano R, Heckman MG, Diehl N, DeVault KR, Achem SR. Nutcracker esophagus: demographic, clinical features, and esophageal tests in 115 patients. Dis Esophagus. 2015; 28:11–18.
44. Almansa C, Heckman MG, DeVault KR, Bouras E, Achem SR. Esophageal spasm: demographic, clinical, radiographic, and manometric features in 108 patients. Dis Esophagus. 2012; 25:214–221.
45. Bassotti G, Pelli MA, Morelli A. Clinical and manometric aspects of diffuse esophageal spasm in a cohort of subjects evaluated for dysphagia and/or chest pain. Am J Med Sci. 1990; 300:148–151.
46. Galmiche JP, Clouse RE, Bálint A, et al. Functional esophageal disorders. Gastroenterology. 2006; 130:1459–1465.
47. Van Handel D, Fass R. The pathophysiology of non-cardiac chest pain. J Gastroenterol Hepatol. 2005; 20(Suppl):S6–S13.
48. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis. Am J Gastroenterol. 2005; 100:1226–1232.
49. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013; 108:308–328. quiz 329.
50. Richter JE, Dalton CB, Bradley LA, Castell DO. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology. 1987; 93:21–28.
51. Davies HA, Lewis MJ, Rhodes J, Henderson AH. Trial of nifedipine for prevention of oesophageal spasm. Digestion. 1987; 36:81–83.
52. Nasrallah SM, Tommaso CL, Singleton RT, Backhaus EA. Primary esophageal motor disorders: clinical response to nifedipine. South Med J. 1985; 78:312–315.
53. Richter JE, Spurling TJ, Cordova CM, Castell DO. Effects of oral calcium blocker, diltiazem, on esophageal contractions. Studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci. 1984; 29:649–656.
54. Cattau EL Jr, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol. 1991; 86:272–276.
55. Drenth JP, Bos LP, Engels LG. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther. 1990; 4:411–416.
56. Richter JE, Dalton CB, Buice RG, Castell DO. Nifedipine: a potent inhibitor of contractions in the body of the human esophagus. Studies in healthy volunteers and patients with the nutcracker esophagus. Gastroenterology. 1985; 89:549–554.
57. Orlando RC, Bozymski EM. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med. 1973; 289:23–25.
58. Millaire A, Ducloux G, Marquand A, Vaksmann G. Nitroglycerin and angina with angiographically normal coronary vessels. Clinical effects and effects on esophageal motility. Arch Mal Coeur Vaiss. 1989; 82:63–68.
59. Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology. 1977; 72:23–27.
60. Kikendall JW, Mellow MH. Effect of sublingual nitroglycerin and long-acting nitrate preparations on esophageal motility. Gastroenterology. 1980; 79:703–706.
61. Mellow MH. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology. 1982; 83:364–370.
62. Lee JI, Park H, Kim JH, Lee SI, Conklin JL. The effect of sildenafil on oesophageal motor function in healthy subjects and patients with nutcracker oesophagus. Neurogastroenterol Motil. 2003; 15:617–623.
63. Bortolotti M, Pandolfo N, Giovannini M, Mari C, Miglioli M. Effect of Sildenafil on hypertensive lower oesophageal sphincter. Eur J Clin Invest. 2002; 32:682–685.
64. Bassotti G, Gaburri M, Imbimbo BP, et al. Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus. Scand J Gastroenterol. 1988; 23:1079–1084.
65. Korsapati H, Bhargava V, Mittal RK. Reversal of asynchrony between circular and longitudinal muscle contraction in nutcracker esophagus by atropine. Gastroenterology. 2008; 135:796–802.
66. Miller LS, Pullela SV, Parkman HP, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol. 2002; 97:1640–1646.
67. Shiwaku H, Inoue H, Beppu R, et al. Successful treatment of diffuse esophageal spasm by peroral endoscopic myotomy. Gastrointest Endosc. 2013; 77:149–150.
68. Khashab MA, Saxena P, Kumbhari V, et al. Peroral endoscopic myotomy as a platform for the treatment of spastic esophageal disorders refractory to medical therapy (with video). Gastrointest Endosc. 2014; 79:136–139.
69. Sharata A, Kurian AA, Dunst CM, Bhayani NH, Reavis KM, Swanström LL. Peroral endoscopic myotomy (POEM) is safe and effective in the setting of prior endoscopic intervention. J Gastrointest Surg. 2013; 17:1188–1192.
70. Mujica VR, Mudipalli RS, Rao SS. Pathophysiology of chest pain in patients with nutcracker esophagus. Am J Gastroenterol. 2001; 96:1371–1377.
71. Peters L, Maas L, Petty D, et al. Spontaneous noncardiac chest pain. Evaluation by 24-hour ambulatory esophageal motility and pH monitoring. Gastroenterology. 1988; 94:878–886.
72. Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemo-sensitivity in humans. Gastroenterology. 1998; 115:1363–1373.
73. Hollerbach S, Bulat R, May A, et al. Abnormal cerebral processing of oesophageal stimuli in patients with noncardiac chest pain (NCCP). Neurogastroenterol Motil. 2000; 12:555–565.
74. Nguyen TM, Eslick GD. Systematic review: the treatment of non-cardiac chest pain with antidepressants. Aliment Pharmacol Ther. 2012; 35:493–500.
75. Doraiswamy PM, Varia I, Hellegers C, et al. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychophar-macol Bull. 2006; 39:15–24.
76. Spinhoven P, Van der Does AJ, Van Dijk E, Van Rood YR. Heart-fo-cused anxiety as a mediating variable in the treatment of non-cardiac chest pain by cognitive-behavioral therapy and paroxetine. J Psychosom Res. 2010; 69:227–235.
77. Varia I, Logue E, O'connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000; 140:367–372.
78. Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994; 330:1411–1417.
79. Lee H, Kim JH, Min BH, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol. 2010; 105:1504–1512.
80. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987; 92:1027–1036.
81. Keefe FJ, Shelby RA, Somers TJ, et al. Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study. Pain. 2011; 152:730–741.
82. Rao SS, Mudipalli RS, Mujica V, Utech CL, Zhao X, Conklin JL. An open-label trial of theophylline for functional chest pain. Dig Dis Sci. 2002; 47:2763–2768.
83. Rao SS, Mudipalli RS, Remes-Troche JM, Utech CL, Zimmerman B. Theophylline improves esophageal chest pain–a randomized, placebo-controlled study. Am J Gastroenterol. 2007; 102:930–938.
84. Coss-Adame E, Erdogan A, Rao SS. Treatment of esophageal (noncardiac) chest pain: an expert review. Clin Gastroenterol Hepatol. 2014; 12:1224–1245.
85. Kumar AR, Katz PO. Functional esophageal disorders: a review of diagnosis and management. Expert Rev Gastroenterol Hepatol. 2013; 7:453–461.
86. van Peski-Oosterbaan AS, Spinhoven P, van Rood Y, van der Does JW, Bruschke AV, Rooijmans HG. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med. 1999; 106:424–429.
87. Mayou RA, Bryant BM, Sanders D, Bass C, Klimes I, Forfar C. A controlled trial of cognitive behavioural therapy for non-cardiac chest pain. Psychol Med. 1997; 27:1021–1031.
88. Jonsbu E, Dammen T, Morken G, Moum T, Martinsen EW. Short-term cognitive behavioral therapy for non-cardiac chest pain and benign palpitations: a randomized controlled trial. J Psychosom Res. 2011; 70:117–123.
89. Jones H, Cooper P, Miller V, Brooks N, Whorwell PJ. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut. 2006; 55:1403–1408.
XML Download